Amgen Inc. (NASDAQ:AMGN) Stock Holdings Boosted by Valmark Advisers Inc.

Valmark Advisers Inc. lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,036 shares of the medical research company’s stock after acquiring an additional 45 shares during the quarter. Valmark Advisers Inc.’s holdings in Amgen were worth $2,315,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Fuller & Thaler Asset Management Inc. boosted its position in shares of Amgen by 1.7% in the third quarter. Fuller & Thaler Asset Management Inc. now owns 11,658 shares of the medical research company’s stock worth $3,133,000 after buying an additional 193 shares during the period. Diversified Trust Co boosted its position in shares of Amgen by 76.8% in the fourth quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock worth $10,857,000 after buying an additional 16,376 shares during the period. Nicolet Advisory Services LLC boosted its position in shares of Amgen by 4.4% in the third quarter. Nicolet Advisory Services LLC now owns 2,805 shares of the medical research company’s stock worth $745,000 after buying an additional 117 shares during the period. Platform Technology Partners boosted its position in shares of Amgen by 7.4% in the third quarter. Platform Technology Partners now owns 5,830 shares of the medical research company’s stock worth $1,567,000 after buying an additional 402 shares during the period. Finally, Traynor Capital Management Inc. boosted its position in shares of Amgen by 9.5% in the fourth quarter. Traynor Capital Management Inc. now owns 18,941 shares of the medical research company’s stock worth $5,455,000 after buying an additional 1,650 shares during the period. 76.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on AMGN shares. Truist Financial reaffirmed a “buy” rating and issued a $320.00 target price on shares of Amgen in a research report on Friday, April 12th. StockNews.com lowered Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. UBS Group cut their price objective on Amgen from $314.00 to $284.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Oppenheimer reiterated an “outperform” rating and set a $350.00 price objective on shares of Amgen in a report on Thursday, February 1st. Finally, Leerink Partnrs lowered Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 7th. Ten research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $296.95.

Amgen Stock Performance

AMGN traded up $0.60 on Friday, hitting $269.98. 2,436,959 shares of the stock traded hands, compared to its average volume of 2,035,139. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $329.72. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The firm has a market capitalization of $144.81 billion, a PE ratio of 21.62, a P/E/G ratio of 2.60 and a beta of 0.58. The business has a fifty day moving average price of $275.10 and a two-hundred day moving average price of $281.45.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, beating the consensus estimate of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The company had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. During the same period in the prior year, the company posted $4.09 EPS. The company’s revenue was up 19.8% compared to the same quarter last year. On average, research analysts predict that Amgen Inc. will post 19.43 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a $2.25 dividend. The ex-dividend date is Thursday, May 16th. This represents a $9.00 annualized dividend and a dividend yield of 3.33%. Amgen’s dividend payout ratio is currently 72.06%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.